This publication for Micar Innovation (Micar21) will appear soon in Diplomatic-World.com
CIDIC (European Centre for Economic, Academic and Cultural Diplomacy) - Diplomatic, Economic, Academic, and Cultural (DEAC) mission to Sofia, 23-26 April 2018, in cooperation with UNICA and BACES, VUB-Brussels Diplomatic Academy and Diplomatic World
MICAR INNOVATION is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through new blockbuster drug molecules for a large class of diseases. It focuses on non-clinical Proof-of-Concepts (POCs) in preclinical R&D and Hit-to-Lead (H2L) achievements in areas such as neuroscience, oncology, cardio-vascularity, dermatology, rare diseases. MICAR21 is their drug discovery platform for small molecule drug candidates. The business model is based on licensing their intellectual property to commercial partners and on the creation new spin out companies.
Micar Innovation received the CIDIC award for its well-chosen positioning in a complex and long value chain, where it can create key-value contributions by delivering non-clinical POCs. The company can be qualified as a fountain of intellectual property and an IP broker for new pharma startups and big pharma industry.